Yahoo Finance

Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours

Oslo, Norway, 16 December 2025– Zelluna (OSE: ZLNA), a company developing off-the-shelf cell therapies for cancer, today announced the publication of preclinical data for its lead candidate, ZI-MA4-1, ...
Yahoo Finance

Zelluna Completes First GMP Batch of ZI-MA4-1, a Novel TCR-NK Cell Therapy, to Treat Patients in Upcoming First-in-Human Trial

On track to file a Clinical Trial Application (CTA) by year end 2025, with initial clinical data expected mid-2026 Important step in developing scalable and accessible ‘off-the-shelf’ cell therapy for ...
Hosted on MSN

Zelluna secures MHRA approval to begin ZIMA-101 trail

Zelluna has received the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) approval for its clinical trial application (CTA) to start the ZIMA-101 first ...
PharmiWeb

Zelluna Reaches Major Milestone with Manufacturing Process Established in Preparation for Clinical Entry of ZI-MA4-1, its Novel TCR-NK Therapy Targeting Solid Tumours

Zelluna Reaches Major Milestone with Manufacturing Process Established in Preparation for Clinical Entry of ZI-MA4-1, its Novel TCR-NK Therapy Targeting Solid Tumours Oslo, Norway, 22 April 2025 – ...
manilatimes

Zelluna Reaches Major Milestone and Submits Clinical Trial Application in the UK for First-in-Human Study of ZI-MA4-1 (ZIMA-101), the World’s First MAGE-A4-Targeting TCR-NK ...

On track for initial clinical data in mid-2026 Marks a pivotal step toward scalable, accessible, off-the-shelf cell therapies for solid tumours Oslo, Norway, 17 December 2025 - Zelluna (OSE: ZLNA), a ...
Finanznachrichten

Zelluna ASA: Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours

Strong preclinical data support planned clinical trial initiation in 2026 Oslo, Norway, 16 December 2025- Zelluna (OSE: ZLNA), a company developing off-the-shelf cell therapies for cancer, today ...